KinderPharm

  • Home
  • Our Company
    • About KinderPharm
    • Why KinderPharm?
    • Management
    • Advisory Board
    • Our Purpose
  • Services
    • Pediatric Regulatory
      • Protocol Development
      • Waivers and Deferrals
      • PIP and PSP Submission
    • Age Appropriate Formulation
      • Pediatric Formulation Development
    • Juvenile Toxicology
      • Juvenile Toxicology Study Design & Conduct
    • Pharmacometrics
      • PK Data Analysis
      • Modeling & Simulation
        • Physiologically Based Pharmacokinetic (PBPK)
        • Pediatric Extrapolation
        • Population PK (POP PK) & Sparse Sampling
    • Clinical Trials
  • Resources
    • FDA Pediatric Information
    • EMA Pediatric Information
    • Other Regions Pediatric Information
  • News & Events
    • News
    • Events
  • Contact Us

FDA Lifts Hold on Epizyme Cancer Drug

by Nick Paul Taylor

The FDA has lifted a partial clinical hold from Epizyme’s tazemetostat. Epizyme got the green light to resume enrollment in trials of the EZH2 inhibitor after showing the FDA data on the risk of secondary malignancies.

Tazemetostat ran into trouble in April when a pediatric cancer patient taking the drug developed a secondary T-cell lymphoblastic lymphoma. The adverse event was the first of its kind seen across the 750 people treated with tazemetostat to date. But, with preclinical studies linking tazemetostat to secondary lymphomas, the FDA halted enrollment in trials of the cancer drug as a precaution.

Sign up for our Newsletter

Epizyme responded to the clinical hold by corralling its data and evidence from the literature into an assessment of the risks posed by tazemetostat. The Massachusetts-based biotech also convened a panel of external experts to review and validate its conclusions.

The response has enabled Epizyme to escape the partial clinical hold within five months. That done, Epizyme has set its sights on getting the multifront clinical development program moving forward again.

“This allows us to turn our full attention to our key priorities: preparing for our first NDA submission for tazemetostat in epithelioid sarcoma and defining our registration path in [follicular lymphoma],” Epizyme CEO Robert Bazemore said in a statement.

However, while the FDA decision is a big boost, Epizyme needs to iron out other regulatory issues before tazemetostat can advance at full speed. Partial clinical holds remain in place in France and Germany. These are significant countries for some of Epizyme’s trials. Seven of the 32 sites activated for Epizyme’s synovial sarcoma phase 2 trial are in France and Germany. The countries account for 29% of the sites in a separate phase 1/2 trial, too.

Shares in Epizyme rose 25% in premarket trading following the news. The surge follows a period in which Epizyme’s stock price fell more than 40% on the back of the partial clinical hold and a failed tazemetostat trial.

PKPD Inc logo

Search this website

Meet Us at Industry Events

Meet with us

Sign up for our Newsletter

Partner With Us For

  • Pediatric Regulatory
    • Protocol Development
    • Waivers and Deferrals
    • PIP and PSP Submission
  • Age Appropriate Formulation
    • Pediatric Formulation Development
  • Juvenile Toxicology
    • Juvenile Toxicology Study Design & Conduct
  • Pharmacometrics
    • PK Data Analysis
    • Modeling & Simulation
      • Physiologically Based Pharmacokinetic (PBPK)
      • Pediatric Extrapolation
      • Population PK (POP PK) & Sparse Sampling
  • Clinical Trials

Read Our Latest Tweets

  • New York Venture Summit - great place to meet new companies and investors. https://t.co/BpvYTwjklH July 19, 2017 11:32 pm
  • Thank you #LifeSciencesPA for hosting the #PAPavilion Looking forward to #BIO2018 in Boston. https://t.co/DMmvmSYItT June 27, 2017 12:35 am
  • Bringing Better Medicines to Children through collaborations at #BIO2017 KinderPharm CEO Dr Graham and American M… https://t.co/YLxQwVZGKw June 22, 2017 12:02 am
  • Follow Us on Twitter

Our Mission

We have a single mission, simply “Bringing Better Medicines to Children” – but as everybody involved in pediatric drug development knows, this is not simple.

Quick Links

  • Services
  • Management
  • Advisory Board
  • Contact Us
  • Careers

Our Locations

US Location
100 Arrandale Blvd. (Suite 101)
Exton, PA 19341 USA

UK Location
40 Bank Street Level 18 Canary Wharf,
London E14 5NR UK

Copyright © 2019 - KinderPharm LLC - Privacy Policy - Terms of Service - Log in